- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction to: PB006: A Natalizumab Biosimilar ; volume:44 ; number:9 ; day:3 ; month:9 ; year:2024 ; pages:729 ; date:9.2024
Clinical drug investigation ; 44, Heft 9 (3.9.2024), 729, 9.2024
- Creator
-
Shirley, Matt
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40261-024-01388-6
- URN
-
urn:nbn:de:101:1-2412232110410.035272978996
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shirley, Matt
- SpringerLink (Online service)
Other Objects (12)
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Correction to: Concurrent management of multiple sclerosis and natalizumab‑induced hepatitis with ofatumumab: a case report
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab
Correction to: Concurrent management of multiple sclerosis and natalizumab‑induced hepatitis with ofatumumab: a case report
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: SB8: A Bevacizumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: MYL-1402O: A Bevacizumab Biosimilar
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
Correction to: Demonstration of Physicochemical and Functional Similarity of the Biosimilar BAT1806/BIIB800 to Reference Tocilizumab